grant
Emulating hypothetical target trials to establish the comparative effectiveness of biologics in asthma
Organization BRIGHAM AND WOMEN'S HOSPITALLocation BOSTON, UNITED STATESPosted 1 Jun 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY2026AddressAdrenal Cortex HormonesAdverse effectsAffectAllergic asthmaAmericanAntibody TherapyAsthmaB Cell Differentiation Factor IB Cell Differentiation Factor I GeneB cell growth factor 2B-Cell Growth Factor-IIBCGF-IIBCGF2BiologicalBiological AgentBiological ProductsBiological Response Modifier TherapyBiological TherapyBlood EosinophilBronchial AsthmaCaringCell BodyCellsCessation of lifeClinicalClinical MarkersClinical Treatment MoabCorticoidsCorticosteroidsDataData BasesDatabasesDeathDiabetes MellitusDiseaseDisorderDrugsEDF GeneEffectivenessElectronic Health RecordEligibilityEligibility DeterminationEnsureEo-CSFEosinophil Differentiation FactorEosinophil Differentiation Factor GeneEosinophilic GranulocyteEosinophilic LeukocyteExtrinsic asthmaFEV1FEV1%VCFEVtForced Expiratory VolumeForced Expiratory Volume 1 TestForced Expiratory Volume in 1 SecondForced expiratory volume functionFrustrationGoalsGuidelinesHeadHealth CareHealth Care SystemsIL-5IL-5 GeneIL5IL5 geneIgA enhancing factorIgEImmunoglobulin EIndividualInterleukin 5 (Colony-Stimulating Factor, Eosinophil) GeneInterleukin 5 PrecursorInterleukin 5 Precursor GeneInterleukin-5Interleukin-5 GeneLinkMarrow EosinophilMedicationMethodologyMonoclonal AntibodiesMorbidityOralOsteoporosisOutcomePFT/FEV1PatientsPharmaceutical EpidemiologyPharmaceutical PreparationsPharmacoepidemiologyPopulationProbabilityProtocol ScreeningProviderPulmonary Function Test/Forced Expiratory Volume 1Randomization trialRandomizedResearchResearch DesignRight to TreatmentsStudy TypeT cell replacing factorT-Cell Replacing FactorT-Cell Replacing Factor GeneTechniquesTherapeuticTherapy trialTimed Forced Vital CapacityTimed Vital CapacityUncertaintyWorkadaptive interventionantagonismantagonistantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentasthma attackasthma exacerbationatopic asthmabiologicbiological therapeuticbiological treatmentbiologically based therapeuticsbiologicsbiopharmaceuticalbiotherapeutic agentbiotherapeuticsbiotherapyclinical biomarkersclinical relevanceclinically relevantclinically useful biomarkerscohortcomparative effectivenesscomparative effectiveness studycomparative effectiveness trialcomparative trialcompare effectivenesscompare treatmentconventional therapyconventional treatmentcostdata basedata collected in real worlddiabetesdoubtdrug epidemiologydrug/agentelectronic health care recordelectronic health medical recordelectronic health plan recordelectronic health registryelectronic medical health recordeosinophileosinophilic asthmaepidemiology research studyepidemiology studyepidemiology surveyevidence baseexacerbation in asthmaexacerbation prone asthmaexacerbation prone asthmaticextrinsic allergic asthmaimprovedimproved outcomeinnovateinnovationinnovativeinsightinterestlung functionmAbsmepolizumabmonoclonal Absmortalitynovelomalizumaboptimal therapiesoptimal treatmentspatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespharmacoepidemiologicpharmacoepidemiologicalpragmatic effectiveness trialpragmatic trialpreferencepulmonary functionrandomisationrandomizationrandomized trialrandomly assignedreal world datarecruitrespiratorysoundstudy designsynergismtreatment comparisontreatment strategy
Description preview
PROJECT SUMMARY/ABSTRACT
Asthma is a leading cause of morbidity in the US and worldwide, affecting almost 10% of the US
population. Individuals with severe asthma, who are uncontrolled on conventional therapy,
account for a disproportionate share of asthma-related morbidity and mortality. For these
patients, the advent of multiple monoclonal…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click